| Title |
|
|
|
Pharmacokinetic evaluation of the aripiprazole (once-monthly) injection for the treatment of bipolar disorder
|
|
| Author |
|
|
|
|
|
| Abstract |
|
|
|
| Introduction: Bipolar disorder is a severe, chronic psychiatric disorder with a need for long-term treatment. Patient nonadherence is frequent and poses a major problem in maintenance therapy. Aripiprazole once-monthly long-acting injectable (AOM LAI) is a recently US Food and Drug Administration-approved treatment option for maintenance therapy that could be of great value. Areas covered: This paper reviews the pharmacokinetic, efficacy and safety data for AOM LAI in bipolar disorder. Expert opinion: AOM LAI is a safe and efficacious treatment option in the maintenance therapy of bipolar I disorder. However, further research is still needed to determine the position of AOM LAI relative to other available treatment options. |
|
|
| Language |
|
|
|
English
|
|
| Source (journal) |
|
|
|
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY |
|
| Publication |
|
|
|
2018
|
|
| Volume/pages |
|
|
|
14:10(2018), p. 999-1005
|
|
| ISI |
|
|
|
000447620100002
|
|
| Pubmed ID |
|
|
|
30141352
|
|
| Full text (Publisher's DOI) |
|
|
| |
|
| Full text (open access) |
|
|
| |
|